Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas

Journal of Neuro-Oncology

Volumn 58, Issue 2, 2002, Pages 107-114

  Terada, K ^a   Tamiya, T ^a   Daido, S ^a   Kambara, H ^a   Tanaka, H ^a   Ono, Y ^a   Matsumoto, K ^a   Ito, S ^a   Ouchida, M ^a   Ohmoto, T ^a   Shimizu, K ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Allelic loss; Brain tumor; DMBT1; NEURL; Prognosis; PTEN

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ALLELE; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER SURVIVAL; CHROMOSOME 10Q; CLINICAL ARTICLE; CORRELATION FUNCTION; FEMALE; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MALE; PROGNOSIS; SILVER STAINING; STATISTICAL ANALYSIS; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; ASTROCYTOMA; BRAIN NEOPLASMS; FEMALE; GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0036069508     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016017711033     Document Type: Article

References (50)

1. Report of the Medical Research Council Brain Tumour Working Party. Prognostic factors for high-grade malignant glioma: Development of a prognostic index
2. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A Joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study
3. Neuropathology of malignant gliomas
4. Necrosis as a prognostic factor in glioblastoma multiforme
5. Gemistocytic astrocytomas: A reappraisal
6. Malignant astrocytomas with homozygous CDKN/p16 gene deletions have higher KI-67 proliferation indices
7. Accumulation of wild-type p53 in astrocytomas is associated with increased p21 expression
8. Expression of cell-cycle regulator p27Kip1 correlates with survival in patients with astrocytoma
9. High cyclin E/low p27Kip1 expression is associated with poor prognosis in astrocytomas
10. Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization
11. Gene amplification in human gliomas
12. A tiger behind many doors: Multiple genetic pathways to malignant glioma
13. Molecular pathways in the formation of gliomas
14. Alterations of the TP53 gene in human gliomas
15. Prognostic factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor gene products on survival
16. Genetic subtype of human malignant astrocytoma correlate with survival
17. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss
18. Cytogenetics of human brain tumours
19. Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS and MXI1 in human glioblastoma multiforme
20. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades
21. New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26
22. Deletion mapping of gliomas suggests the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q
23. Loss of chromosome 10 is an independent prognostic factor in high grade gliomas
24. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
25. DMBT1, and new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumors
26. Identification of a candidate tumor suppressor gene at 10q23.3 that is mutated in multiple advanced cancers, MMAC-1
27. A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors
28. Identification of a human homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region
29. MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells
30. AZU-1: A candidate breast tumor suppressor and biomarker for tumor progression
31. Fast and sensitive silver staining of DNA in polyacrylamide gels
32. Histological typing of tumours of the central nervous system
33. Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: Relationship to prognostic significance
34. Loss of heterozygosity of chromosome 10p in human glioblastomas
35. Deletion mapping of chromosome 10 in human glioma
36. Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer
37. Lack of DMBT1 expression in esophageal, gastric and colon cancers
38. Allele loss on chromosomes 10 and 17p and epidermal growth factor receptor gene amplification in human malignant astrocytoma related to prognosis
39. Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers
40. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas
41. Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografs
42. Tumor suppressor gene alterations in malignant gliomas: Histopathological associations and prognostic evaluation
43. Mutational analysis of the PTEN gene in gliomas: Molecular and pathological correlations
44. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme
45. Differential expression of MMAC/PTEN in glioblastoma multiforme: Relationship to localization and prognosis
46. Functional and molecular analyses of 10q deletions in human gliomas
47. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter
48. The molecular genetics of central nervous system tumors
49. Immunobiochemical characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67
50. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: Relationship and prognostic value